X

Zyden Gentec Ltd. Stock Analysis

Small Cap
Evaluated by 112 users | BSE: 530091 | NSE: |
Pharmaceuticals & Drugs
Zyden Gentec was incorporated on April 26, 1994 under the companies Act 1956 as Overseas Capital Private Limited. The name of the company was changed to Overseas Capital Limited on conversion into public limited company on November 11, 1994 and to Zyden Gentec Limited on July 16, 2004. The...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Return on Capital Employed 3.66%3.31%-14.85%-1.85%-0.98%-0.08%1.66%-0.07%-2.42%-12.86%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 17.512.19.57.61.60.30.40.10.71.2
Y-o-Y Gr. Rt.--30.9%-21.4%-20.6%-78.9%-78.6%5.9%-86.1%1380%55.4%
Adjusted EPS (Rs.) 0.04-0.04-0.74-0.13-0.05-0.010.060-0.28-0.26
Y-o-Y Gr. Rt.--200%NANANANANA-100%NANA
Book Value per Share (Rs.) 3.393.342.332.272.232.222.152.151.761.08
Adjusted Net Profit 0.1-0.1-4.1-0.7-0.300.30-1.5-1.4
Net Op. Cash Flow (Rs. Cr.) 4-1.6-1.83.70.30-2.4-0.5-5.30.1
Debt to Cash Flow from Ops 0.99-6.24-6.333.2237.91-4,897.5-3.32-14.65-0.8523.21
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Zyden Gentec Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales -26.1%-6.3%47.3%55.4%
Adjusted EPS -223.1%NA-263%NA
Book Value per Share -11.9-13.5-20.5-38.6
Share Price -12.2% -2.7% - -
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Return on Equity (%) 1.25-1.22-36.94-5.68-2.03-0.342.82-0.11-14.19-18.21
Operating Profit Margin (%) 4.249.74-30.54-13.37-81.14-115.4589.24-24.2248.01-37.71
Net Profit Margin (%) 0.6-0.89-43-9.67-15.89-12.2496.27-24.58-207.46-125.14
Debt to Equity 0.461.190.870.940.80.780.660.610.470.34
Working Capital Days 1833385437713,36615,09915,8511,05,0657,4023,641
Cash Conversion Cycle 1011522011879743,505-6,60,63624,4271,861889
Entity Percentage Holding
Institutions 1.61%
Non-Institutions 98.39%
Pledged *58.420.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Zyden Gentec's performance infers:

Zyden Gentec earnings have grown by 0%, whereas share price has depreciated -2.7% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Zyden Gentec share prices over the last 10 years. Here is what we found out:

Zyden Gentec share price has depreciated -15.2% annually over the past ten years.

Zyden Gentec was incorporated on April 26, 1994 under the companies Act 1956 as Overseas Capital Private Limited. The name of the company was changed to Overseas Capital Limited on conversion into public limited company on November 11, 1994 and to Zyden Gentec Limited on July 16, 2004. The company was promoted by RK Dhar.

Initially the company was engaged in providing financial services and is presently engaged in the manufacturing of pharmaceuticals and fine chemicals.

Product

Zyden Gentec was incorporated on April 26, 1994 under the companies Act 1956 as Overseas Capital Private Limited. The name of the company was changed to Overseas Capital Limited on conversion into public limited company on November 11, 1994 and to Zyden Gentec Limited on July 16, 2004. The company was promoted by RK Dhar.

Initially the company was engaged in providing financial services and is presently engaged in the manufacturing of pharmaceuticals and fine chemicals.

Product range of the company includes:

The company's principal activity is to manufacture pharmaceutical products and to provide concultancy services. The company operates in two segments namely Manufacturing & Allied Activities and Financial, Investment & Allied Activities. The products of the company include specialized chemicals, bulk drugs, compounds and intermediates

  • Drotaverine HCL
  • Levocetrizine
  • Ketoconazole
  • Sildenafil Citrate
  • Glucosamine
  • Ciprofloxacin HCL
  • Enro Floxacin
  • Bypyridine
  • Guaifenesin
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719
© 2020 MoneyWorks4me.com | All Rights Reserved